证券代码：600227 证券简称：赤天化 编号：2025-038 贵州赤天化股份有限公司 关于提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称及是否为上市公司关联人：被担保人贵州大秦肿 瘤医院有限公司（以下简称"大秦医院"）和贵州赤天化桐梓化工有 限公司（以下简称"桐梓化工"）系公司的全资子公司。 ●本次担保金额及已实际为其提供的担保余额：①2025年5月， 公司对大秦医院增加担保金额为1,300万元，截止至2025年5月30日， 公司累计为大秦医院提供担保余额为63,173.94万元；②2025年5月， 公司对桐梓化工增加担保金额为7,726万元，截止至2025年5月30日， 公司累计为桐梓化工提供担保余额为53,723万元；2025年5月，公司 提供担保的子公司归还借款金额5,363万元，截止至2025年5月30日， 公司及公司控股子公司对外担保总额为116,896.94万元，对外担保均 为公司为报表合并范围内的子公司提供的担保。 ●本次担保是否有反担保：否 ●对外担保逾期 ...

Core Viewpoint - The legal opinion letter confirms that the convening and voting procedures of Guizhou Chitianhua Co., Ltd.'s 2024 annual shareholders' meeting comply with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][14][15] Group 1: Meeting Procedures - The meeting was convened by the company's ninth board of directors and publicly announced on April 29, 2025, detailing the time, location, voting methods, and other relevant information [3][4] - The meeting was held on May 19, 2025, combining on-site and online voting, with specific time slots for online voting through the Shanghai Stock Exchange [4][5] Group 2: Attendance and Voting Qualifications - A total of 364 shareholders (or their proxies) attended the meeting, representing 654,866,410 shares, which is 38.9559% of the total voting shares [5][6] - The qualifications of the attendees were verified and found to be compliant with legal and regulatory requirements [5][6] Group 3: Voting Results - The meeting passed several resolutions, including the 2024 Board of Directors' Work Report, with a majority approval rate of 98.8137% [7] - Other resolutions, such as the 2024 Financial Budget and the proposal for external financing guarantees for subsidiaries, also received high approval rates, ranging from 98.4097% to 98.9625% [9][10][12][13] - The voting results for small shareholders were separately counted and disclosed, ensuring transparency in the voting process [13]

Meeting Overview - The shareholders' meeting of Guizhou Chitianhua Co., Ltd. was held on May 19, 2025, at the company's headquarters in Guiyang [1] - A total of 38.9559% of the shares were represented at the meeting [1] Voting Results - All proposed resolutions were passed with significant majority votes, including: - 98.8137% approval for the first resolution with 647,098,294 votes in favor [1] - 98.8771% approval for the second resolution with 647,513,294 votes in favor [1] - 98.8688% approval for the third resolution with 647,458,574 votes in favor [1] - 98.8695% approval for the fourth resolution with 647,463,474 votes in favor [1] - 98.9582% approval for the fifth resolution with 648,044,394 votes in favor [2] Legal Compliance - The meeting was convened and conducted in accordance with the Company Law and the Articles of Association, ensuring all procedures were legally valid [4] - The legal representatives confirmed the legitimacy of the meeting and the voting process [4]

Core Points - The company is currently involved in a lawsuit as the plaintiff, seeking payment of 17,892,267.12 yuan plus interest from the defendant for unpaid goods [1][2] - The case is at the first-instance judgment stage, and the company is unable to determine the impact on current or future profits until the appeal period is over [1][2] - The court found insufficient evidence to support the company's claims, leading to a judgment against the company [2] Summary by Sections Lawsuit Details - The company filed a civil lawsuit against an agricultural company for the recovery of unpaid goods amounting to 17,892,267.12 yuan, along with interest calculated at 1.5 times the one-year Loan Prime Rate (LPR) from the date of the lawsuit [1][2] - The lawsuit includes claims for litigation costs to be borne by the defendant [1] Court Ruling - The court applied a simplified procedure for the hearing and found that the evidence presented by the company was insufficient to support its claims [2] - The company has the right to appeal the judgment within fifteen days of receiving the court's decision [2] Impact on Financials - The company is currently unable to assess the impact of the lawsuit on its profits for the current or future periods due to the ongoing appeal process [1][2] - As of the announcement date, the company has no other undisclosed significant litigation or arbitration matters [2]

证券代码：600227 证券简称：赤 天 化 编号：2025-037 贵州赤天化股份有限公司 关于公司提起诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生负面影响：目前案件所处阶段为一 审判决，尚处于上诉期内，暂无法准确判断对公司本期利润或期后利 润的影响，公司将及时对该诉讼事项的进展情况履行相关信息披露义 务，敬请广大投资者注意投资风险。 2025 年 5 月 19 日，贵州赤天化股份有限公司（以下简称"公司" 或"原告"）收到贵州省贵阳市云岩区人民法院（以下简称"云岩区 人民法院"）《民事判决书》（2025）黔 0103 民初 3320 号，现将有关 情况公告如下： 1、驳回原告贵州赤天化股份有限公司的诉讼请求。 2、案件受理费减半收取 64577 元，由原告贵州赤天化股份有限 公司负担。 如不服本判决，可在判决书送达之日起十五日内向本院递交上诉 状，并按对方当事人人数提出副本，上诉于贵州省贵阳市中级人民法 院。 三、本次诉讼对公司本期利润或期后利润等的影响 一、本次 ...

北京植德律师事务所 关于贵州赤天化股份有限公司 2024 年年度股东大会的 法律意见书 植德京（会）字[2025]0056号 二〇二五年五月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Offices Tower, No.1 Dongzhimen South Street,Dongcheng District, Beijing 100007 P.R.C. 电话（Tel）: 010-56500900 传真（Fax）: 010-56500999 www.meritsandtree.com 北京植德律师事务所 关于贵州赤天化股份有限公司 2024 年年度股东大会的 法律意见书 植德京（会）字[2025]0056 号 致：贵州赤天化股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席 并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证 ...

证券代码：600227 证券简称：赤天化 公告编号：2025-036 贵州赤天化股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 1、公司在任董事9人，出席9人，其中独立董事范其勇以视频方式出席会议； 2、公司在任监事3人，出席3人； 3、董事会秘书先正红出席会议；其他高级管理人员列席会议。 二、 议案审议情况 (一) 非累积投票议案 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 364 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 654,866,410 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 38.9559 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，董事长丁林洪主持，采取现场投票及网络投票相结 (一) 股东大会召开的时间：2025 年 5 月 19 日 (二) ...

Overview - The company announced a supplementary notice regarding the payment of guarantee fees to related parties and the associated transactions [1] Transaction Details - The board of directors approved a proposal for the company to pay guarantee fees to related parties, which will be submitted for review at the 2024 annual general meeting [1] - The company’s wholly-owned subsidiary, Guizhou Daqin Tumor Hospital Co., Ltd., will receive a fixed asset loan from the Agricultural Development Bank of China, with guarantees provided by Guizhou Chitianhua Group and Zunyi Tiantong Plastic Co., Ltd. [1] - The guarantee fee payment is based on the assessed value of the collateral provided for the loan [2] Asset Evaluation - The assessed value of the collateral, which includes 66 properties and commercial spaces, is determined to be 200.8363 million yuan, reflecting a decrease of 22.23% from the previous bank assessment [2] - The decline in assessed value is attributed to reduced usable life of the assets and a sluggish real estate market [2] Adjusted Guarantee Fee Structure - The pricing basis for the guarantee fee will be adjusted according to the new assessed value [3] - The maximum estimated total guarantee fee is now capped at 34.6443 million yuan, calculated based on the new assessed value over a maximum period of 11.5 years [5] Future Implications - The adjustment in the assessed value of the collateral will lead to a reduction in the guarantee fees payable by the company [5] - The company aims to negotiate with the Agricultural Development Bank to release the guarantees by 2028, contingent on the hospital's operational performance [5]

Core Viewpoint - The evaluation of fixed assets, specifically buildings and structures owned by Guizhou Chitianhua Group Co., Ltd., is set for April 30, 2025, with detailed assessments provided for various properties [1][2][3][4][5][6]. Group 1: Asset Evaluation Details - The evaluation includes multiple properties such as factories, offices, and other facilities located in the Chishui City Chemical Road area, with ownership attributed to Guizhou Chitianhua Group Co., Ltd. [1][2][3]. - The assessment lists the original value, net value, and estimated value of each property, along with their respective construction dates and structural types [1][2][3][4]. - The total assessed value of the properties is approximately 133,062,800.00 RMB, with a detailed breakdown of individual properties and their respective values [6]. Group 2: Property Characteristics - Properties include various types of buildings such as factories, offices, and service facilities, with specific details on their construction area and rights [1][2][3][4]. - The evaluation also notes the age and condition of the buildings, indicating the depreciation and appreciation rates for each asset [1][2][3]. - The properties are primarily located in the Chishui City area, with specific land use rights documented for each asset [1][2][3][4].

Core Viewpoint - Guizhou Chitianhua Co., Ltd. reported a challenging financial year for 2024, with a net loss attributed to various operational factors, despite some growth in revenue from its chemical and medical service segments [1][2][3]. Financial Performance - The company achieved operating revenue of CNY 238,006.12 million in 2024, with a net loss attributable to shareholders of CNY -8,669.35 million [1][19]. - The chemical segment generated revenue of CNY 226,020.86 million, contributing a net profit of CNY 13,086.61 million, while the medical services segment reported a revenue of CNY 10,430.55 million with a net loss of CNY -12,867.21 million [1][3]. - The coal segment saw an increase in production and sales, with a slight rise in prices compared to the previous year [1]. Asset and Liability Overview - As of December 31, 2024, total assets amounted to CNY 483,556.81 million, reflecting a 2.58% increase from the beginning of the year [2][20]. - The company's debt ratio rose to 47.37%, an increase of 3.57% from the previous year [2]. Production and Sales Data - The company sold 66.11 million tons of urea, a year-on-year increase of 6.36%, and 32.81 million tons of methanol, up 46.16% [2][29]. - The production of synthetic ammonia, methanol, and urea increased by 7.06%, 42.36%, and 7.98% respectively compared to the previous year [3][29]. Future Outlook - For 2025, the company plans to produce 55.80 million tons of urea and 30 million tons of methanol, with a projected total revenue of CNY 217,830.13 million and a net loss of CNY -7,118.09 million [9][33]. - The company anticipates challenges due to market fluctuations in commodity prices, particularly for urea and methanol, which are influenced by international and domestic conditions [34].